These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 8893121)
21. New β-lactam-β-lactamase inhibitor combinations in clinical development. Shlaes DM Ann N Y Acad Sci; 2013 Jan; 1277():105-14. PubMed ID: 23346860 [TBL] [Abstract][Full Text] [Related]
22. Suppression of the growth of six potentially-pathogenic mycobacteria by beta-lactam/beta-lactamase-inhibitors. Prabhakaran K; Harris EB; Randhawa B Microbios; 1997; 91(366):7-14. PubMed ID: 9467917 [TBL] [Abstract][Full Text] [Related]
23. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams. Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554 [TBL] [Abstract][Full Text] [Related]
24. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? Harris PN; Tambyah PA; Paterson DL Lancet Infect Dis; 2015 Apr; 15(4):475-85. PubMed ID: 25716293 [TBL] [Abstract][Full Text] [Related]
25. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Bush K Int J Antimicrob Agents; 2015 Nov; 46(5):483-93. PubMed ID: 26498989 [TBL] [Abstract][Full Text] [Related]
26. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii. Karaoglan I; Zer Y; Bosnak VK; Mete AO; Namiduru M J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334 [TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic properties of beta-lactamase inhibitors. de la Pena A; Derendorf H Int J Clin Pharmacol Ther; 1999 Feb; 37(2):63-75. PubMed ID: 10082170 [TBL] [Abstract][Full Text] [Related]
29. Novel β-Lactam/β-Lactamase inhibitor combinations vs alternative antibiotics in the treatment of complicated urinary tract infections: A meta-analysis of randomized controlled trials. Lu LC; Lai CC; Chang SP; Lan SH; Hung SH; Lin WT Medicine (Baltimore); 2020 May; 99(19):e19960. PubMed ID: 32384444 [TBL] [Abstract][Full Text] [Related]
31. Ureidopenicillins and beta-lactam/beta-lactamase inhibitor combinations. Bush LM; Johnson CC Infect Dis Clin North Am; 2000 Jun; 14(2):409-33, ix. PubMed ID: 10829263 [TBL] [Abstract][Full Text] [Related]
32. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Rodríguez-Baño J; Navarro MD; Retamar P; Picón E; Pascual Á; Clin Infect Dis; 2012 Jan; 54(2):167-74. PubMed ID: 22057701 [TBL] [Abstract][Full Text] [Related]
33. Clinical trials of extended spectrum penicillin/beta-lactamase inhibitors in the treatment of intra-abdominal infections. European and North American experience. Wilson SE; Nord CE Am J Surg; 1995 May; 169(5A Suppl):21S-26S. PubMed ID: 7755164 [TBL] [Abstract][Full Text] [Related]
34. Effects of beta-lactamase-mediated antimicrobial resistance: the role of beta-lactamase inhibitors. Maddux MS Pharmacotherapy; 1991; 11(2 ( Pt 2)):40S-50S. PubMed ID: 2041831 [TBL] [Abstract][Full Text] [Related]